PH12023550016A1 - Methods of treatment of tuberous sclerosis complex - Google Patents
Methods of treatment of tuberous sclerosis complexInfo
- Publication number
- PH12023550016A1 PH12023550016A1 PH1/2023/550016A PH12023550016A PH12023550016A1 PH 12023550016 A1 PH12023550016 A1 PH 12023550016A1 PH 12023550016 A PH12023550016 A PH 12023550016A PH 12023550016 A1 PH12023550016 A1 PH 12023550016A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- tuberous sclerosis
- treatment
- sclerosis complex
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Fruits And Vegetables (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035313P | 2020-06-05 | 2020-06-05 | |
| PCT/EP2021/065075 WO2021245281A1 (en) | 2020-06-05 | 2021-06-04 | Methods of treatment of tuberous sclerosis complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12023550016A1 true PH12023550016A1 (en) | 2024-03-11 |
Family
ID=76325558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2023/550016A PH12023550016A1 (en) | 2020-06-05 | 2021-06-04 | Methods of treatment of tuberous sclerosis complex |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11684613B2 (https=) |
| EP (1) | EP4161512A1 (https=) |
| JP (2) | JP2023528895A (https=) |
| KR (2) | KR20230027145A (https=) |
| CN (1) | CN116056701A (https=) |
| AU (1) | AU2021285273A1 (https=) |
| BR (1) | BR112022024760A2 (https=) |
| CA (1) | CA3180794A1 (https=) |
| CL (1) | CL2022003435A1 (https=) |
| IL (2) | IL322310A (https=) |
| MX (1) | MX2022015407A (https=) |
| PH (1) | PH12023550016A1 (https=) |
| WO (1) | WO2021245281A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022024760A2 (pt) * | 2020-06-05 | 2023-03-07 | Noema Pharma Ag | Métodos de tratamento do complexo de esclerose tuberosa |
| EP4658268A1 (en) * | 2023-02-02 | 2025-12-10 | Noema Pharma AG | Methods of treatment of dravet syndrome |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA80888C2 (en) | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| NZ551253A (en) | 2004-06-01 | 2010-07-30 | Hoffmann La Roche | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists |
| MY148217A (en) * | 2006-12-21 | 2013-03-29 | Hoffmann La Roche | Polymorphs of a mglur5 receptor antagonist |
| US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20120039999A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| BR112022024760A2 (pt) * | 2020-06-05 | 2023-03-07 | Noema Pharma Ag | Métodos de tratamento do complexo de esclerose tuberosa |
-
2021
- 2021-06-04 BR BR112022024760A patent/BR112022024760A2/pt unknown
- 2021-06-04 IL IL322310A patent/IL322310A/en unknown
- 2021-06-04 MX MX2022015407A patent/MX2022015407A/es unknown
- 2021-06-04 CN CN202180057592.9A patent/CN116056701A/zh active Pending
- 2021-06-04 CA CA3180794A patent/CA3180794A1/en active Pending
- 2021-06-04 WO PCT/EP2021/065075 patent/WO2021245281A1/en not_active Ceased
- 2021-06-04 KR KR1020237000370A patent/KR20230027145A/ko not_active Ceased
- 2021-06-04 PH PH1/2023/550016A patent/PH12023550016A1/en unknown
- 2021-06-04 KR KR1020257024877A patent/KR20250116184A/ko active Pending
- 2021-06-04 IL IL298709A patent/IL298709A/en unknown
- 2021-06-04 AU AU2021285273A patent/AU2021285273A1/en active Pending
- 2021-06-04 JP JP2022574675A patent/JP2023528895A/ja active Pending
- 2021-06-04 EP EP21730918.6A patent/EP4161512A1/en active Pending
-
2022
- 2022-12-02 US US18/061,239 patent/US11684613B2/en active Active
- 2022-12-05 CL CL2022003435A patent/CL2022003435A1/es unknown
-
2023
- 2023-05-11 US US18/315,723 patent/US11998535B2/en active Active
-
2024
- 2024-04-22 US US18/641,640 patent/US20250099445A1/en active Pending
-
2025
- 2025-05-19 JP JP2025082998A patent/JP2025122066A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021285273A1 (en) | 2023-01-19 |
| CA3180794A1 (en) | 2021-12-09 |
| IL298709A (en) | 2023-02-01 |
| US20230100520A1 (en) | 2023-03-30 |
| CN116056701A (zh) | 2023-05-02 |
| JP2025122066A (ja) | 2025-08-20 |
| US20230277513A1 (en) | 2023-09-07 |
| US11998535B2 (en) | 2024-06-04 |
| JP2023528895A (ja) | 2023-07-06 |
| BR112022024760A2 (pt) | 2023-03-07 |
| KR20250116184A (ko) | 2025-07-31 |
| US20250099445A1 (en) | 2025-03-27 |
| US11684613B2 (en) | 2023-06-27 |
| IL322310A (en) | 2025-09-01 |
| EP4161512A1 (en) | 2023-04-12 |
| MX2022015407A (es) | 2023-05-16 |
| WO2021245281A1 (en) | 2021-12-09 |
| CL2022003435A1 (es) | 2023-10-20 |
| KR20230027145A (ko) | 2023-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501222A1 (en) | Cyclic dinucleotides as sting (stimulator of interferon genes) agonists | |
| PH12021550310A1 (en) | Novel sulfonamideurea compounds | |
| MX2020010407A (es) | Benzotiofenos y compuestos relacionados como agonistas de sting. | |
| MX385054B (es) | Piridinas sustituidas con heteroarilo y metodos de uso. | |
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| MX2019011530A (es) | Saxitoxinas 11,13-modificadas para el tratamiento del dolor. | |
| MX2020002806A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso. | |
| PH12020550585A1 (en) | Sting modulator compounds, and methods of making and using | |
| MX2022001690A (es) | Compuestos deuterados para usarse en el tratamiento del cancer. | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| MX392829B (es) | Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales | |
| PH12023550016A1 (en) | Methods of treatment of tuberous sclerosis complex | |
| CR20230413A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| MX2022002418A (es) | Composiciones y metodos de tratamiento de enfermedades vasculares. | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| MX2019010101A (es) | Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
| MX2023004955A (es) | Compuestos de aminotiazol deuterados como compuestos antiviricos. | |
| EA201891808A1 (ru) | Трис-амидные соединения и композиции, содержащие их | |
| MX2024010480A (es) | Uso de inhibidor de captacion triple para el tratamiento de la depresion atipica. | |
| RU2014123690A (ru) | Терапевтическое средство при артрозе | |
| MX2023003035A (es) | Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme. | |
| PH12023550204A1 (en) | Methods of treatment of trigeminal neuralgia | |
| MX2025008911A (es) | Metodos de tratamiento del sindrome de dravet |